Treatment of Bipolar Disorder During Pregnancy
J Clin Psychiatry 2007;68(suppl 9):4-9
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
The treatment of bipolar disorder during pregnancy or in those women who wish to conceive poses
a unique set of dilemmas with which clinicians should be familiar. Given the teratogenicity of some
psychotropic medications used to treat bipolar disorder and incomplete reproductive safety data for
agents frequently employed to manage the illness, patients and clinicians should collaborate as they
weigh options regarding appropriate pharmacologic therapy during pregnancy. Ultimately, risk-benefit
decisions are made that must factor in the risk of relapse of psychiatric illness during pregnancy and its
attendant morbidity versus the risk of fetal exposure to these agents. No clinical decision is risk-free,
and patients with comparable information about risks and benefits of treatment options may make different
decisions. However, awareness of the latest reproductive safety data across the family of compounds
used to treat bipolar disorder, including antipsychotics, antidepressants, mood stabilizers, and
anticonvulsants, allows for the most informed decisions. This article (1) describes the treatment dilemmas
faced by bipolar women who are either pregnant or who wish to conceive, (2) reviews the teratogenic
risks associated with commonly used psychotropic medications used to treat the illness, and
(3) provides some clinical guidelines for treating this population during pregnancy.